| budesonide/formoterol / Generic mfg. |
NCT00651651: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5 |
|
|
| Completed | 3 | 450 | US | budesonide/formoterol, Symbicort, budesonide, formoterol | AstraZeneca | Asthma | | 09/03 | | |
NCT00652002: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5 |
|
|
| Completed | 3 | 450 | US | budesonide/formoterol, Symbicort, budesonide, formoterol | AstraZeneca | Asthma | | 01/04 | | |
NCT00652392: Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM |
|
|
| Completed | 3 | 750 | US | budesonide/formoterol, Symbicort, budesonide and placebo | AstraZeneca | Asthma | | 06/04 | | |
NCT00646321: Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT |
|
|
| Completed | 3 | 540 | US | budesonide/formoterol (Symbicort), Symbicort, budesonide | AstraZeneca | Asthma | | 08/04 | | |
NCT00651768: Titratable Dosing in Moderate to Severe Asthmatics |
|
|
| Completed | 3 | 570 | US | budesonide/formoterol, Symbicort, Symbicort pMDI + budesonide HFA pMDI | AstraZeneca | Asthma | | 01/05 | | |
| Completed | 3 | 1200 | US | budesonide/formoterol (Symbicort), Symbicort, fluticasone/salmeterol (Advair), Advair | AstraZeneca | Asthma | | 01/05 | | |
NCT00238784: SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults |
|
|
| Completed | 3 | 1300 | Canada | Budesonide/formoterol Turbuhaler | AstraZeneca | Asthma | 10/05 | 10/05 | | |
SYMPHONIE, NCT00259792: - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults |
|
|
| Completed | 3 | 1000 | Europe | Budesonide/formoterol Turbuhaler, Symbicort | AstraZeneca | Asthma | | 01/06 | | |
| Completed | 3 | 16 | Europe | formoterol, budesonide/formoterol | AstraZeneca | Asthma | | 05/06 | | |
NCT00252863: DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults |
|
|
| Completed | 3 | 1600 | Europe | Symbicort, used twice daily (b.i.d) and as needed (prn), Budesonide Turbuhaler 200 µg, Fluticasone Discus 250 µg, Formoterol Turbuhaler 4.5 µg, Terbutaline Turbuhaler 0.5 mg, Salbutamol pressurized metered dose inhaler (pMDI) 100 µg, Salmeterol Discus 50 µg, Budesonide/Formoterol Turbuhaler 160/4.5 µg, Fluticasone/Salmeterol Discus 250/50 µg, Fluticasone/Salmeterol Discus 500/50 µg, Theophylline 200 mg, Theophylline 300 mg, Singulair 10 mg | AstraZeneca | Asthma | | 05/06 | | |
NCT00242775 / 2004-004905-11: Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg |
|
|
| Completed | 3 | 2100 | Canada, Europe, RoW | Budesonide/formoterol Turbuhaler, Symbicort, Salmeterol/fluticasone Diskus | AstraZeneca | Asthma | | 05/06 | | |
| Completed | 3 | 1000 | Europe | Budesonide/formoterol, Symbicort | AstraZeneca | Asthma | | 08/06 | | |
NCT00235911: Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting |
|
|
| Completed | 3 | 100 | Europe | budesonide/formoterol Turbuhaler | AstraZeneca | Asthma | 10/06 | 12/06 | | |
NCT00252785: Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients |
|
|
| Completed | 3 | 340 | Japan | Budesonide/Formoterol, Symbicort, Budesonide, Theophylline | AstraZeneca | Asthma | | 11/06 | | |
NCT00206154 / 2004-001183-41: A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients |
|
|
| Completed | 3 | 1500 | US, Europe, RoW | Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler | AstraZeneca | Chronic Obstructive Pulmonary Disease | | 12/06 | | |
| Completed | 3 | 1000 | Europe, RoW | Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy, Symbicort | AstraZeneca | Asthma | | 12/06 | | |
| Completed | 3 | 550 | Europe | Budesonide/formoterol, Symbicort® Turbohaler® | AstraZeneca | Asthma | | 12/06 | | |
NCT00255255: Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma |
|
|
| Completed | 3 | 120 | Japan | Budesonide/Formoterol, Symbicort | AstraZeneca | Asthma | 12/06 | 06/07 | | |
NCT00244608 / 2004-004042-41: A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler® |
|
|
| Completed | 3 | 100 | Europe | Budesonide/Formoterol Turbuhaler, Symbicort, Budesonide Turbuhaler (Pulmicort), Terbutaline Turbuhaler | AstraZeneca | Asthma | | 03/07 | | |
NCT00259766: SHARE - Symbicort and Health Economics in a Real Life Evaluation |
|
|
| Completed | 3 | 1970 | Europe | Budesonide, Symbicort, Formoterol, Terbutaline | AstraZeneca | Asthma | | 05/07 | | |
| Completed | 3 | 600 | Canada | Budesonide/formoterol, Symbicort | AstraZeneca | Asthma | | 05/07 | | |
| Completed | 3 | 120 | Europe | budesonide/formoterol, Symbicort, Prednisolone | AstraZeneca | Chronic Obstructive Pulmonary Disease | | 07/07 | | |
NCT00449527: A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects |
|
|
| Completed | 3 | 123 | US | Budesonide/formoterol pMDI, Symbicort, Budesonide HFA pMDI | AstraZeneca | Asthma | | 08/07 | | |
NCT00206167 / 2004-001168-28: A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD |
|
|
| Completed | 3 | 1600 | US, Europe, RoW | Budesonide/formoterol pMDI, Formoterol Turbuhaler | AstraZeneca | Chronic Obstructive Pulmonary Disease | | 09/07 | | |
NCT00421122: Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD |
|
|
| Completed | 3 | 315 | RoW | budesonide/formoterol (Symbicort), Symbicort® Turbuhaler, budesonide (Pulmicort), Pulmicort® Turbuhaler, terbutaline sulfate (Bricasol), Bricasol pMDI | AstraZeneca | Chronic Obstructive Pulmonary Disease | | 11/07 | | |
NCT00449501: A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects |
|
|
| Completed | 3 | 134 | US | Budesonide/formoterol pMDI, Symbicort, Budesonide HFA pMDI | AstraZeneca | Asthma | | 11/07 | | |
| Completed | 3 | 107 | Europe, RoW | Budesonide/formoterol pMDI 40/2.25ug + spacer, Budesonide/formoterol pMDI 40/2.25 ug | AstraZeneca | Asthma | 02/08 | 02/08 | | |
| Completed | 3 | 742 | Europe | Symbicort Turbuhaler, Symbicort pMDI, Pulmicort Turbuhaler | AstraZeneca | Bronchial Asthma | 04/08 | 04/08 | | |
NCT00419757: An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma |
|
|
| Completed | 3 | 558 | US | Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI | AstraZeneca | Asthma | 06/08 | 06/08 | | |
PASSION, NCT00628758: A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma |
|
|
| Completed | 3 | 430 | RoW | Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid, Astmerol inh 25 mcg/dosage, 60-120 dosage, Astmerol maksihaler 50 mcg/dosage, 28-60 dosage, Serevent diskus 50 mcg/dosage, 60 dosage, Serevent inh 25 mcg/dosage, 60 dosage, Foradil inh kap 12 mcg/dosage, 60 caps, Foradil inh 12 mcg/dosage, 50-100 dosage, Foradil combi 200 mcg, Foradil combi 400 mcg, Oxis turbuhaler 4.5-9 mcg/dosage, 60 dosage, Ventofor 12mg/60 inh.caps, Seretide disc 100-250-500 mcg/dosage 60 dosage, Symbicort 160/4.5 mcg/60-120 dosage, 320/9mcg/60 dosage | AstraZeneca | Asthma | 09/08 | 09/08 | | |
| Terminated | 3 | 654 | Europe | Symbicort (budesonide/formoterol) Turbuhaler, Conventional treatment | AstraZeneca | Asthma, Bronchial | | 10/08 | | |
| Completed | 3 | | Canada | budesonide and budesonide/formoterol | Laval University, AstraZeneca | Asthma | | | | |
NCT00837967: Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients |
|
|
| Completed | 3 | 25 | Japan | Symbicort Turbuhaler, Terbutaline Turbuhaler | AstraZeneca | Asthma | 07/09 | 07/09 | | |
NCT00419744: A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD |
|
|
| Completed | 3 | 1200 | US, RoW | Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler | AstraZeneca | Chronic Obstructive Pulmonary Disease | 08/09 | 08/09 | | |
NCT00419952: A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma. |
|
|
| Completed | 3 | 742 | US | Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI | AstraZeneca | Asthma | 11/09 | 11/09 | | |
NCT01099722 / 2009-017223-25: Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma |
|
|
| Completed | 3 | 261 | Europe, RoW | Flutiform, Symbicort Turbohaler | Mundipharma Research Limited | Asthma | 11/10 | 07/11 | | |
| Completed | 3 | 2091 | Japan, Europe, RoW | Symbicort Turbuhaler, Terbutaline Turbuhaler | AstraZeneca | Asthma | 02/11 | 02/11 | | |
SUMIRE, NCT01069289: Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients |
|
|
| Completed | 3 | 1293 | Japan, Europe, RoW | Budesonide/formoterol (Symbicort Turbuhaler), Symbicort Turbuhaler, Formoterol (Oxis Turbuhaler), Oxis Turbuhaler | AstraZeneca | Chronic Obstructive Pulmonary Disease | 03/11 | 03/11 | | |
NCT01070784: A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan |
|
|
| Completed | 3 | 328 | Japan | Symbicort Turbuhaler (Budesonide/formoterol), Symbicort Turbuhaler, Drug: any available COPD treatment; investigator to decide | AstraZeneca | Chronic Obstructive Pulmonary Disease | 10/11 | 10/11 | | |
| Terminated | 3 | 113 | Europe | Foster® 100/6 µg/unit dose, Symbicort® Turbohaler® 200/6 μg/actuation | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 11/12 | 11/12 | | |
| Completed | 3 | 12460 | Europe, US, RoW | Symbicort pMDI, budesonide pMDI | AstraZeneca | Asthma | 10/15 | 10/15 | | |
RISE, NCT02157935 / 2014-000593-19: Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease |
|
|
| Completed | 3 | 2026 | Europe, US, RoW | Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler | AstraZeneca | COPD Patients | 02/16 | 02/16 | | |
CHASE 3, NCT02091986 / 2013-005293-22: A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg |
|
|
| Completed | 3 | 882 | US, Europe, RoW | Symbicort pMDI, Budesonide pMDI, Active comparator | AstraZeneca | Asthma | 04/16 | 04/16 | | |
